---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:11:39.595380'
end_time: '2025-12-14T17:20:08.886568'
duration_seconds: 509.29
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: AGRN
  gene_symbol: AGRN
  uniprot_accession: O00468
  protein_description: 'RecName: Full=Agrin; Contains: RecName: Full=Agrin N-terminal
    110 kDa subunit; Contains: RecName: Full=Agrin C-terminal 110 kDa subunit; Contains:
    RecName: Full=Agrin C-terminal 90 kDa fragment; Short=C90; Contains: RecName:
    Full=Agrin C-terminal 22 kDa fragment; Short=C22; Flags: Precursor;'
  gene_info: Name=AGRN; Synonyms=AGRIN;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881);
    EGF-like_dom. (IPR000742); FacI_MAC. (IPR003884); Fol_N. (IPR003645)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 19
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O00468
- **Protein Description:** RecName: Full=Agrin; Contains: RecName: Full=Agrin N-terminal 110 kDa subunit; Contains: RecName: Full=Agrin C-terminal 110 kDa subunit; Contains: RecName: Full=Agrin C-terminal 90 kDa fragment; Short=C90; Contains: RecName: Full=Agrin C-terminal 22 kDa fragment; Short=C22; Flags: Precursor;
- **Gene Information:** Name=AGRN; Synonyms=AGRIN;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881); EGF-like_dom. (IPR000742); FacI_MAC. (IPR003884); Fol_N. (IPR003645)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AGRN" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AGRN' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AGRN** (gene ID: AGRN, UniProt: O00468) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O00468
- **Protein Description:** RecName: Full=Agrin; Contains: RecName: Full=Agrin N-terminal 110 kDa subunit; Contains: RecName: Full=Agrin C-terminal 110 kDa subunit; Contains: RecName: Full=Agrin C-terminal 90 kDa fragment; Short=C90; Contains: RecName: Full=Agrin C-terminal 22 kDa fragment; Short=C22; Flags: Precursor;
- **Gene Information:** Name=AGRN; Synonyms=AGRIN;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** ConA-like_dom_sf. (IPR013320); EGF-like_Ca-bd_dom. (IPR001881); EGF-like_dom. (IPR000742); FacI_MAC. (IPR003884); Fol_N. (IPR003645)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AGRN" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AGRN' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AGRN** (gene ID: AGRN, UniProt: O00468) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status and verification
- Target identity verified: AGRN (UniProt O00468) encodes human agrin, a large extracellular matrix heparan sulfate proteoglycan with multiple EGF-like and laminin G-like domains; alternative splicing yields secreted vs transmembrane isoforms. This aligns with the UniProt description and domain architecture. Mechanistically, agrin binds LRP4 and activates MuSK at the neuromuscular junction (NMJ) (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 1-2).

Comprehensive research report on human AGRN (agrin; UniProt O00468)

1) Key concepts and definitions (current understanding)
- Identity and structure: Agrin is a ~220 kDa extracellular matrix heparan sulfate proteoglycan encoded by AGRN. It contains multiple domains, including EGF-like repeats and C-terminal laminin G-like modules that mediate interactions with receptors and basement-membrane components. Alternative splicing produces neural isoforms with “z” inserts (z+) that are synaptogenic and muscle/non-neural isoforms with reduced synaptogenic activity (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 1-2).
- Processing and fragments: Neuronal neurotrypsin cleaves agrin to generate C-terminal fragments, including a 22-kDa C-terminal agrin fragment (CAF22). Circulating CAFs are measurable in plasma and have been studied as biomarkers of neuromuscular junction (NMJ) degeneration and sarcopenia (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 6-7, li2024roleofagrin pages 9-10).
- Primary NMJ function: Neural (z+) agrin released from motor neurons binds LRP4 on myofibers, inducing LRP4–MuSK complex formation and MuSK activation, which triggers clustering of acetylcholine receptors (AChRs). This pathway is required for NMJ differentiation and maintenance (2024 preprint; https://doi.org/10.26434/chemrxiv-2024-rkqvt; Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (iyer2024rarediseasesinsights pages 32-34, kutay2025masterarbeit|mastersthesis pages 88-90, li2024roleofagrin pages 1-2).
- Synaptic basal lamina and binding partners: Agrin concentrates in the synaptic basal lamina and binds α-dystroglycan and laminins via its laminin G-like domains, stabilizing the dystrophin–glycoprotein complex (DGC) and the postsynaptic apparatus (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 7-9).
- Renal basement membranes: In the kidney, agrin is a major heparan sulfate proteoglycan of the glomerular basement membrane (GBM), contributing to its negative charge and to podocyte–basement-membrane linkage via dystroglycan. Some reports note preserved filtration despite agrin loss, indicating context-dependent contributions to charge selectivity and integrity (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 7-9, li2024roleofagrin pages 10-11).

2) Recent developments and latest research (2023–2024 priority)
- Updated mechanistic synthesis: A 2024 review integrates structural and functional advances in agrin biology across tissues, emphasizing canonical LRP4–MuSK signaling at the NMJ, and expanding roles in regeneration (cardiac, cartilage, cornea, hematopoiesis) and in matrix-mediated mechano-signaling (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 1-2, li2024roleofagrin pages 6-7, li2024roleofagrin pages 7-9).
- Autoimmunity landscape: 2024 landscape analysis of MG highlights agrin as a disease-linked autoantigen alongside LRP4 and MuSK; experimental immunization with agrin induces MG-like weakness and NMJ changes in mice, supporting causal relevance (Jun 2024; https://doi.org/10.26434/chemrxiv-2024-rkqvt) (iyer2024rarediseasesinsights pages 32-34, iyer2024rarediseasesinsights pages 109-111).
- Cardiac regeneration: Summaries of preclinical studies show that recombinant agrin administered post-myocardial infarction in mice and swine improves ejection fraction, reduces scar, and promotes cardiomyocyte proliferation, acting via LRP4 and α-dystroglycan with ERK/YAP activation (Jan 2024; https://doi.org/10.3390/medsci12010008) (hamsho2024thecurrentstate pages 8-10). The 2024 review also collates these studies and proposes translational potential (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 4-5, li2024roleofagrin pages 9-10).
- Biomarkers: Recent syntheses emphasize circulating C-terminal agrin fragments (CAF/CAF22) as emerging biomarkers of sarcopenia and NMJ decline; multiple cohorts have established reference intervals and associations with muscle status (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 6-7, li2024roleofagrin pages 9-10, li2024roleofagrin pages 10-11).

3) Current applications and real-world implementations
- Clinical biomarker development: CAF/CAF22 quantification is being explored for muscle denervation and sarcopenia risk stratification (reference interval and disease cohorts reported). Post-stroke and kidney-transplant applications have been evaluated, indicating feasibility of clinical testing workflows (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 9-10, li2024roleofagrin pages 10-11).
- Translational cardiology: Recombinant agrin is under evaluation in large-animal models with dosing regimens (e.g., single intramyocardial dose ≈33 μg/kg) that improved function and reduced remodeling after ischemia–reperfusion injury—informing real-world therapeutic design (Jan 2024; https://doi.org/10.3390/medsci12010008) (hamsho2024thecurrentstate pages 8-10).

4) Expert opinions and analysis from authoritative sources
- 2024 review perspective: Agrin integrates structural ECM roles with receptor-mediated signaling to coordinate synaptogenesis and organ repair; the therapeutic window likely relies on isoform, dose, tissue distribution, and crosstalk with receptors such as LRP4, α-dystroglycan, and downstream YAP/ERK pathways. The review cautions that precise mechanisms and context-dependence (e.g., renal vs synaptic BM) remain active areas of inquiry (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 1-2, li2024roleofagrin pages 7-9).
- MG landscape analysis: Agrin/LRP4 autoantibodies define clinically relevant MG subsets; alongside MUSK and AChR, these specificities motivate precision diagnostics and tailored therapy, reinforcing the centrality of the agrin–LRP4–MuSK axis at the human NMJ (Jun 2024; https://doi.org/10.26434/chemrxiv-2024-rkqvt) (iyer2024rarediseasesinsights pages 32-34, iyer2024rarediseasesinsights pages 109-111).

5) Relevant statistics and data from recent studies
- MG autoantibody landscape: Multiple independent studies summarized in 2024 report the presence of agrin and LRP4 autoantibodies in subsets of MG; experimental induction of anti-agrin antibodies causes MG-like disease in mice, supporting pathogenicity (Jun 2024; https://doi.org/10.26434/chemrxiv-2024-rkqvt) (iyer2024rarediseasesinsights pages 32-34, iyer2024rarediseasesinsights pages 109-111). Quantitative prevalence percentages by antibody class vary across cohorts and assays and were not uniformly reported in the available excerpts; therefore precise prevalence estimates are not included here.
- Cardiac regeneration effects: In preclinical mouse and swine myocardial infarction models, recombinant agrin improved systolic function (ejection fraction, fractional shortening), reduced scar size, and enhanced wall thickness after one or two local doses, with mechanistic evidence for ERK and YAP activation through LRP4/α-dystroglycan (Jan 2024; https://doi.org/10.3390/medsci12010008) (hamsho2024thecurrentstate pages 8-10).
- CAF/CAF22 biomarker associations: Across recent studies collated in 2024, higher circulating CAF associates with sarcopenia and muscle decline; studies have established reference intervals and assessed CAF as a renal function biomarker in transplant recipients and as a marker post-acute stroke (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 9-10, li2024roleofagrin pages 10-11, li2024roleofagrin pages 6-7).

Mechanistic pathways and localization
- NMJ signaling pathway: Neuronal z+ agrin engages LRP4, which complexes with and activates MuSK; MuSK phosphorylation triggers downstream scaffolding and cytoskeletal changes that cluster AChRs at the postsynaptic membrane, essential for synapse formation and stability (2024; https://doi.org/10.3892/ijmm.2024.5422; 2024; https://doi.org/10.26434/chemrxiv-2024-rkqvt) (li2024roleofagrin pages 1-2, iyer2024rarediseasesinsights pages 32-34, kutay2025masterarbeit|mastersthesis pages 88-90).
- Synaptic basal lamina scaffold: Agrin’s C-terminal laminin G-like domains bind α-dystroglycan and laminins, anchoring the basement membrane to the DGC and organizing postsynaptic components, consistent with its concentration in the synaptic basal lamina (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 7-9).
- Kidney GBM: Agrin contributes to GBM composition and charge. Its interactions with podocyte dystroglycan support basement membrane integrity; however, the exact contribution to filtration charge selectivity may vary with context, as some studies note preserved function despite agrin loss (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 7-9, li2024roleofagrin pages 10-11).

Clinical and translational relevance
- Congenital myasthenic syndromes (CMS): AGRN loss-of-function impairs MuSK activation and AChR clustering, producing NMJ transmission defects characteristic of specific CMS genotypes (synthetic summary across recent analyses) (Jun 2024; https://doi.org/10.26434/chemrxiv-2024-rkqvt) (iyer2024rarediseasesinsights pages 32-34, iyer2024rarediseasesinsights pages 109-111).
- Autoimmune MG: Autoantibodies to agrin and LRP4 define MG subsets and disrupt agrin–LRP4–MuSK signaling; detection supports diagnosis and may guide selection of targeted immunotherapies (Jun 2024; https://doi.org/10.26434/chemrxiv-2024-rkqvt) (iyer2024rarediseasesinsights pages 32-34, iyer2024rarediseasesinsights pages 109-111).
- Biomarkers: CAF/CAF22 are promising for assessing NMJ denervation and sarcopenia; evidence extends to stroke and renal-transplant populations with established assay feasibility (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 9-10, li2024roleofagrin pages 10-11, li2024roleofagrin pages 6-7). Data specifically quantifying post–COVID-19 CAF22 dynamics were not extractable from the present evidence set; thus, this remains a partial gap here.
- Regenerative medicine: Recombinant agrin shows multi-modal benefits in preclinical cardiac repair (e.g., improved EF, reduced scar, angiogenesis, immunomodulation) with mechanistic links to LRP4/α-dystroglycan–ERK/YAP pathways (Jan 2024; https://doi.org/10.3390/medsci12010008; Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (hamsho2024thecurrentstate pages 8-10, li2024roleofagrin pages 4-5, li2024roleofagrin pages 9-10).

Embedded summary table of key findings and sources
| Topic | Key finding | Mechanism/partners | Evidence and citation IDs | URL/DOI | Year |
|---|---|---|---|---|---|
| Identity / domains & HSPG nature | AGRN encodes agrin, a ~220 kDa extracellular matrix heparan-sulfate proteoglycan with multiple EGF-like and laminin G–like domains and alternatively spliced secreted vs transmembrane isoforms. | HSPG glycosylation and domain architecture (EGF-like, LamG) determine ECM interactions and localization. | (li2024roleofagrin pages 1-2) | https://doi.org/10.3892/ijmm.2024.5422 | 2024 |
| NMJ pathway (LRP4–MuSK, AChR clustering) & isoforms | Neuronal (z+) agrin binds LRP4 to activate MuSK, driving postsynaptic AChR clustering; neural vs muscle isoforms determine synapse-inducing activity. | Agrin–LRP4–MuSK complex formation triggers MuSK phosphorylation and downstream AChR clustering machinery. | (li2024roleofagrin pages 1-2, iyer2024rarediseasesinsights pages 32-34, kutay2025masterarbeit|mastersthesis pages 88-90) | https://doi.org/10.3892/ijmm.2024.5422, https://doi.org/10.26434/chemrxiv-2024-rkqvt | 2024 |
| Synaptic basal lamina localization & dystroglycan/laminin interactions | Agrin concentrates in the synaptic basal lamina where it binds α-dystroglycan and laminins, linking the basement membrane to the postsynaptic membrane and stabilizing the DGC. | Laminin G–like C-terminal domains mediate DAG1 (α-dystroglycan) and laminin interactions; contributes to postsynaptic scaffold stability. | (li2024roleofagrin pages 7-9, hamsho2024thecurrentstate pages 8-10, li2024roleofagrin pages 1-2) | https://doi.org/10.3892/ijmm.2024.5422, https://doi.org/10.3390/medsci12010008 | 2024 |
| Kidney GBM presence & roles | Agrin is a major heparan-sulfate proteoglycan of the glomerular basement membrane (GBM), contributing to negative charge, podocyte–BM linkage, and BM integrity though some studies report preserved filtration despite loss. | HSPG negative charge and interactions with podocyte dystroglycan link the cytoskeleton to the GBM; proteolytic fragments may modulate renal pathology. | (li2024roleofagrin pages 7-9, li2024roleofagrin pages 10-11) | https://doi.org/10.3892/ijmm.2024.5422 | 2024 |
| Disease links: MG autoantibodies & AGRN-related CMS | Autoantibodies to agrin or LRP4 occur in subsets of myasthenia gravis patients and disrupt agrin–LRP4–MuSK signaling; loss‑of‑function AGRN mutations cause congenital myasthenic syndromes with NMJ defects. | Autoantibodies block agrin–LRP4/MuSK interactions; pathogenic AGRN mutations impair MuSK activation and AChR clustering. | (iyer2024rarediseasesinsights pages 32-34, kutay2025masterarbeit|mastersthesis pages 88-90) | https://doi.org/10.26434/chemrxiv-2024-rkqvt | 2024 |
| Circulating C‑terminal agrin fragments (CAF / CAF22) as biomarkers | Neurotrypsin cleavage of agrin releases C‑terminal fragments (e.g., CAF22) measurable in plasma; elevated CAF associates with sarcopenia, NMJ decline and has been studied in clinical cohorts. | Proteolytic release by neurotrypsin produces CAFs that reflect NMJ proteolysis/denervation and correlate with muscle loss. | (li2024roleofagrin pages 6-7, li2024roleofagrin pages 9-10, li2024roleofagrin pages 10-11) | https://doi.org/10.3892/ijmm.2024.5422 | 2024 |
| Cardiac regeneration with recombinant agrin (mouse & swine) | Recombinant agrin delivered after myocardial infarction promotes cardiomyocyte cell-cycle re-entry, reduces scar formation and improves cardiac function in mouse and porcine models. | Agrin signals via LRP4 and α‑dystroglycan, activating ERK/YAP and remodeling ECM, angiogenesis and immunomodulation to enable CM dedifferentiation/proliferation. | (hamsho2024thecurrentstate pages 8-10, li2024roleofagrin pages 4-5, li2024roleofagrin pages 9-10) | https://doi.org/10.3390/medsci12010008, https://doi.org/10.3892/ijmm.2024.5422 | 2024 |


*Table: Concise table of recent (2023–2024) evidence for human AGRN (agrin) covering identity, NMJ mechanism, GBM roles, disease links, CAF biomarkers, and cardiac regeneration, with primary citations and DOIs for follow-up.*

References (URLs and dates)
- Li X, Xu Y, Si J-X, Gu F, Ma Y-Y. Role of Agrin in tissue repair and regeneration: From mechanisms to therapeutic opportunities. Int J Mol Med. Sep 2024. https://doi.org/10.3892/ijmm.2024.5422 (li2024roleofagrin pages 1-2, li2024roleofagrin pages 6-7, li2024roleofagrin pages 7-9, li2024roleofagrin pages 10-11, li2024roleofagrin pages 9-10, li2024roleofagrin pages 4-5).
- Iyer K, Tenchov R, Sasso J, et al. Rare diseases: landscape analysis with spotlight on myasthenia gravis (includes agrin/LRP4 autoantibodies). ChemRxiv. Jun 2024. https://doi.org/10.26434/chemrxiv-2024-rkqvt (iyer2024rarediseasesinsights pages 32-34, iyer2024rarediseasesinsights pages 109-111, iyer2024rarediseasesinsightsa pages 32-34).
- Kutay AK. Master’s thesis summarizing agrin–LRP4–MuSK NMJ signaling and related literature. 2025. Repository entry cited in evidence (kutay2025masterarbeit|mastersthesis pages 88-90).
- Hamsho K, Broadwin M, Stone CR, Sellke FW, Abid MR. Current state of extracellular matrix therapy for ischemic heart disease (includes recombinant agrin animal data). Medical Sciences. Jan 2024. https://doi.org/10.3390/medsci12010008 (hamsho2024thecurrentstate pages 8-10).

Notes on mandatory verification
- Gene symbol AGRN matches UniProt O00468 (human agrin). The organism is Homo sapiens. Domain architecture and HSPG nature align with literature descriptions (EGF-like, laminin G-like). If other “agrin/AGRN” usages are encountered in non-human organisms or ambiguous contexts, they were excluded per the verification requirement (Sep 2024; https://doi.org/10.3892/ijmm.2024.5422) (li2024roleofagrin pages 1-2).

References

1. (li2024roleofagrin pages 1-2): Xiang Li, Yuan Xu, Jing-Xing Si, Fang Gu, and Ying-Yu Ma. Role of agrin in tissue repair and regeneration: from mechanisms to therapeutic opportunities (review). International Journal of Molecular Medicine, Sep 2024. URL: https://doi.org/10.3892/ijmm.2024.5422, doi:10.3892/ijmm.2024.5422. This article has 2 citations and is from a peer-reviewed journal.

2. (li2024roleofagrin pages 6-7): Xiang Li, Yuan Xu, Jing-Xing Si, Fang Gu, and Ying-Yu Ma. Role of agrin in tissue repair and regeneration: from mechanisms to therapeutic opportunities (review). International Journal of Molecular Medicine, Sep 2024. URL: https://doi.org/10.3892/ijmm.2024.5422, doi:10.3892/ijmm.2024.5422. This article has 2 citations and is from a peer-reviewed journal.

3. (li2024roleofagrin pages 9-10): Xiang Li, Yuan Xu, Jing-Xing Si, Fang Gu, and Ying-Yu Ma. Role of agrin in tissue repair and regeneration: from mechanisms to therapeutic opportunities (review). International Journal of Molecular Medicine, Sep 2024. URL: https://doi.org/10.3892/ijmm.2024.5422, doi:10.3892/ijmm.2024.5422. This article has 2 citations and is from a peer-reviewed journal.

4. (iyer2024rarediseasesinsights pages 32-34): Kavita Iyer, Rumiana Tenchov, Janet Sasso, Krittika Ralhan, Jyotsna Jotshi, Dmitrii Polshakov, Ankush Maind, and Qiongqiong Angela Zhou. Rare diseases: insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, huntington’s disease, and myasthenia gravis. ChemRxiv, Jun 2024. URL: https://doi.org/10.26434/chemrxiv-2024-rkqvt, doi:10.26434/chemrxiv-2024-rkqvt. This article has 2 citations.

5. (kutay2025masterarbeit|mastersthesis pages 88-90): AK Kutay. Masterarbeit| master's thesis. Unknown journal, 2025.

6. (li2024roleofagrin pages 7-9): Xiang Li, Yuan Xu, Jing-Xing Si, Fang Gu, and Ying-Yu Ma. Role of agrin in tissue repair and regeneration: from mechanisms to therapeutic opportunities (review). International Journal of Molecular Medicine, Sep 2024. URL: https://doi.org/10.3892/ijmm.2024.5422, doi:10.3892/ijmm.2024.5422. This article has 2 citations and is from a peer-reviewed journal.

7. (li2024roleofagrin pages 10-11): Xiang Li, Yuan Xu, Jing-Xing Si, Fang Gu, and Ying-Yu Ma. Role of agrin in tissue repair and regeneration: from mechanisms to therapeutic opportunities (review). International Journal of Molecular Medicine, Sep 2024. URL: https://doi.org/10.3892/ijmm.2024.5422, doi:10.3892/ijmm.2024.5422. This article has 2 citations and is from a peer-reviewed journal.

8. (iyer2024rarediseasesinsights pages 109-111): Kavita Iyer, Rumiana Tenchov, Janet Sasso, Krittika Ralhan, Jyotsna Jotshi, Dmitrii Polshakov, Ankush Maind, and Qiongqiong Angela Zhou. Rare diseases: insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, huntington’s disease, and myasthenia gravis. ChemRxiv, Jun 2024. URL: https://doi.org/10.26434/chemrxiv-2024-rkqvt, doi:10.26434/chemrxiv-2024-rkqvt. This article has 2 citations.

9. (hamsho2024thecurrentstate pages 8-10): Khaled Hamsho, Mark Broadwin, Christopher R. Stone, Frank W. Sellke, and M. Ruhul Abid. The current state of extracellular matrix therapy for ischemic heart disease. Medical Sciences, 12:8, Jan 2024. URL: https://doi.org/10.3390/medsci12010008, doi:10.3390/medsci12010008. This article has 9 citations and is from a poor quality or predatory journal.

10. (li2024roleofagrin pages 4-5): Xiang Li, Yuan Xu, Jing-Xing Si, Fang Gu, and Ying-Yu Ma. Role of agrin in tissue repair and regeneration: from mechanisms to therapeutic opportunities (review). International Journal of Molecular Medicine, Sep 2024. URL: https://doi.org/10.3892/ijmm.2024.5422, doi:10.3892/ijmm.2024.5422. This article has 2 citations and is from a peer-reviewed journal.

11. (iyer2024rarediseasesinsightsa pages 32-34): K Iyer, R Tenchov, J Sasso, K Ralhan, and J Jotshi. Rare diseases: insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, huntington's disease, and myasthenia gravis. Unknown journal, 2024.

## Citations

1. li2024roleofagrin pages 1-2
2. li2024roleofagrin pages 7-9
3. hamsho2024thecurrentstate pages 8-10
4. li2024roleofagrin pages 6-7
5. li2024roleofagrin pages 9-10
6. iyer2024rarediseasesinsights pages 32-34
7. li2024roleofagrin pages 10-11
8. iyer2024rarediseasesinsights pages 109-111
9. li2024roleofagrin pages 4-5
10. iyer2024rarediseasesinsightsa pages 32-34
11. https://doi.org/10.3892/ijmm.2024.5422
12. https://doi.org/10.26434/chemrxiv-2024-rkqvt;
13. https://doi.org/10.26434/chemrxiv-2024-rkqvt
14. https://doi.org/10.3390/medsci12010008
15. https://doi.org/10.3892/ijmm.2024.5422;
16. https://doi.org/10.3390/medsci12010008;
17. https://doi.org/10.3892/ijmm.2024.5422,
18. https://doi.org/10.3390/medsci12010008,
19. https://doi.org/10.26434/chemrxiv-2024-rkqvt,